{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T23:13:25Z","timestamp":1774653205702,"version":"3.50.1"},"reference-count":37,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2006,7,19]],"date-time":"2006-07-19T00:00:00Z","timestamp":1153267200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2006,9]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold><jats:italic>Background<\/jats:italic>:\u2002Recently investigators have worked to identify prognostic factors in non\u2010Hodgkin's lymphoma (NHL) so an appropriate therapeutic plan can be put in action. The aim of the present study was to assess the prognostic significance of serum soluble tumor necrosis factor receptor (sTNF\u2010R) 2 in aggressive NHL.<jats:italic>Methods<\/jats:italic>:\u2002One hundred and ten consecutive patients with aggressive NHL who were previously untreated (diffuse large B\u2010cell lymphoma; 94, peripheral T\u2010cell lymphoma; 16) were prospectively enrolled in this study between 1997 and 2002. The patients were treated with 6\u20138\u2003cycles of CHOP or THP\u2010COP regimens.<jats:italic>Results<\/jats:italic>:\u2002High serum sTNF\u2010Rs level was associated with some poor prognostic factors and low complete remission rate. Patients with high sTNF\u2010R1 (4\u2003ng\/mL and over) and sTNF\u2010R2 (15\u2003ng\/mL and over) at onset had significantly lower survival rates (5\u2003yr: 19%, 19%) than those with low sTNF\u2010R1 (under 4\u2003ng\/mL) and sTNF\u2010R2 (under 15\u2003ng\/mL) (62% and 69%), respectively (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.0005 and 0.0001). Multivariate analysis employing sTNF\u2010R2 and some conventional prognostic factors demonstrated that a combination of sTNF\u2010R2 and performance status, and that of sTNF\u2010R2, sIL\u20102R, and LDH were significant prognostic factors for poor overall survival and for poor event\u2010free survival, respectively. In addition, we attempted to use sTNF\u2010R2 in combination with the international prognostic index (IPI). The patients in the high risk group and those with high sTNF\u2010R2 in the low\u2010intermediate (LI)\/high\u2010intermediate (HI) risk group had significantly lower survival rates than the patients in the low risk group and those with low sTNF\u2010R2 in LI\/HI risk group (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.0001).<jats:italic>Conclusions<\/jats:italic>:\u2002The results suggest that a high serum sTNF\u2010R2 level predicts a poor prognosis in aggressive NHL and may be a useful biomarker for selecting appropriate treatment when used in combination with the IPI.<\/jats:p>","DOI":"10.1111\/j.1600-0609.2006.00702.x","type":"journal-article","created":{"date-parts":[[2006,7,20]],"date-time":"2006-07-20T15:13:05Z","timestamp":1153408385000},"page":"217-225","source":"Crossref","is-referenced-by-count":32,"title":["Serum\u2010soluble tumor necrosis factor receptor 2 (sTNF\u2010R2) level determines clinical outcome in patients with aggressive non\u2010Hodgkin's lymphoma"],"prefix":"10.1111","volume":"77","author":[{"given":"Naoe","family":"Goto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Tsurumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Takemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michio","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Senji","family":"Kasahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiro","family":"Kanemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiki","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahito","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuru","family":"Seishima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Takami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisataka","family":"Moriwaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,19]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"e_1_2_5_3_2","first-page":"1163","article-title":"Cytokine production (IL\u20101\u03b1, IL\u20101\u03b2, and TNF\u03b1) and endothelial cell activation (ELAM\u20101 and HLA\u2010DR) in reactive lymphadentis, Hodgkin's disease, and in non\u2010Hodgkin's lymphomas","volume":"17","author":"Ruco LP","year":"1990","journal-title":"Am J Pathol"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V73.5.1242.1242"},{"key":"e_1_2_5_5_2","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1182\/blood.V81.3.752.752","article-title":"Expression and functional role of tumor necrosis factor receptors on leukemic cells from patients with type B chronic lymphoproliferative disorders","volume":"81","author":"Trentin L","year":"1993","journal-title":"Blood"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.5483\/BMBRep.2005.38.3.281"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.175.2.323"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6101(96)00026-3"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1990.tb07526.x"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.2.499"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2"},{"key":"e_1_2_5_12_2","first-page":"109","volume-title":"World Health Organization Classification of Tumors, Pathology and Genetics Tumors of Haematopoietic and Lymphoid Tissues","author":"Jaffe ES","year":"2001"},{"key":"e_1_2_5_13_2","first-page":"1860","article-title":"Report of the committee on Hodgkin's disease staging classification","volume":"31","author":"Carbone PP","year":"1971","journal-title":"Cancer Res"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-003-0508-9"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00253970"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950220410"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199012001-00005"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2002.01654.x"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_5_21_2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life\u2010tables (with discussions)","volume":"34","author":"Cox DR","year":"1972","journal-title":"J Roy Stat Soc (Ser B)"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.3.1131"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.1.423"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199708213370804"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.5.1202"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/1096-8652(200008)64:4<257::AID-AJH4>3.0.CO;2-2"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/35000501"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-119-8-199310150-00001"},{"key":"e_1_2_5_29_2","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1182\/blood.V75.4.1011.1011","article-title":"Increased serum levels of tumor necrosis factor \u03b1 precede major complications of bone marrow transplantation","volume":"75","author":"Holler E","year":"1990","journal-title":"Blood"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.5181059.x"},{"key":"e_1_2_5_31_2","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1182\/blood.V79.12.3362.bloodjournal79123362","article-title":"Phase I\u2010II trial of a monoclonal anti\u2010tumor necrosis factor \u03b1 antibody for the treatment of refractory severe acute graft\u2010versus disease","volume":"79","author":"Herve P","year":"1992","journal-title":"Blood"},{"key":"e_1_2_5_32_2","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.4049\/jimmunol.152.3.1347","article-title":"Inhibition of TNF by a TNF receptor immunoadhesion comparison to an anti\u2010TNF monoclonal antibody","volume":"152","author":"Haak\u2010Frendcho M","year":"1994","journal-title":"J Immunol"},{"key":"e_1_2_5_33_2","first-page":"243","article-title":"Soluble tumor necrosis factor (sTNF) receptors: a possible prognostic marker for bone transplantation\u2010related complications","volume":"2","author":"Or R","year":"1996","journal-title":"Cytokines Mol Ther"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/1096-8652(200010)65:2<105::AID-AJH3>3.0.CO;2-R"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.iy.10.040192.002211"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19870901)60:5<1127::AID-CNCR2820600535>3.0.CO;2-A"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199009000-00033"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830240825"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2006.00702.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2006.00702.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:34:46Z","timestamp":1736469286000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2006.00702.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7,19]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["10.1111\/j.1600-0609.2006.00702.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2006.00702.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7,19]]}}}